ProPhase Labs, Inc. (PRPH) financial statements (2022 and earlier)

Company profile

Business Address 711 STEWART AVE, SUITE 200
NEW YORK, NY 11530
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17,26322,86136,25136,2588,45512,2635,876
Cash and cash equivalents8,4088,53317,67732,7276,81610,8602,537
Short-term investments8,85514,32818,5743,5311,6391,4033,339
Receivables37,70810,6806,64414,3443,1552,9991,930
Inventory, net of allowances, customer advances and progress billings4,6008,51015,16916,0263,0392,1382,047
Inventory4,6008,51015,16916,0263,0392,1382,047
Assets held-for-sale, not part of disposal group     176176
Other undisclosed current assets1,7461,8524286191,238334213
Total current assets:61,31743,90358,49267,24715,88717,91010,242
Noncurrent Assets
Operating lease, right-of-use asset4,4024,4844,5644,6464,731  
Property, plant and equipment5,9476,4546,9147,0783,5782,1232,133
Intangible assets, net (including goodwill)16,56112,9471,9182,0262,135  
Goodwill5,7091,385901901901  
Intangible assets, net (excluding goodwill)10,85211,5621,0171,1251,234  
Prepaid expense4604604604602,084  
Other noncurrent assets608608248248240  
Other undisclosed noncurrent assets 3,7743,7273,7392,7503,000 
Total noncurrent assets:27,97828,72717,83118,19715,5185,1232,133
TOTAL ASSETS:89,29572,63076,32385,44431,40523,03312,375
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,0262,3947,1147,7803,771836844
Accounts payable7,0262,3947,1147,7803,771836844
Deferred revenue2,0341,517     
Other liabilities3,8071,7416,2119,7671,731898439
Other undisclosed current liabilities2,6574,280849742792411112
Total current liabilities:15,5249,93214,17418,2896,2942,1451,395
Noncurrent Liabilities
Long-term debt and lease obligation14,23814,32814,29514,34114,3939,990 
Long-term debt, excluding current maturities10,04010,0769,9949,9939,9919,990 
Operating lease, liability4,1984,2524,3014,3484,402  
Liabilities, other than long-term debt90510612114916213786
Deferred revenue90510612114916213786
Total noncurrent liabilities:15,14314,43414,41614,49014,55510,12786
Total liabilities:30,66724,36628,59032,77920,84912,2721,481
Stockholders' equity
Stockholders' equity attributable to parent58,62848,26447,73352,66510,55610,76110,894
Common stock16161616141414
Treasury stock, value(48,407)(47,490)(47,490)(47,490)(47,490)(47,490)(47,490)
Additional paid in capital104,552103,80799,265102,73561,67460,89460,611
Accumulated other comprehensive income (loss)(175)(122)(89)(22)(11)(4)4
Retained earnings (accumulated deficit)2,642(7,947)(3,969)(2,574)(3,631)(2,653)(2,245)
Total stockholders' equity:58,62848,26447,73352,66510,55610,76110,894
TOTAL LIABILITIES AND EQUITY:89,29572,63076,32385,44431,40523,03312,375

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues45,1579,4729,14215,2715,1633,8403,623
Cost of revenue
(Cost of Goods and Services Sold)
(20,539)(5,495)(4,676)(6,344)(3,293)(2,798)(2,344)
Gross profit:24,6183,9774,4668,9271,8701,0421,279
Operating expenses(10,941)(7,624)(5,916)(7,706)(4,535)(1,609)(1,220)
Other undisclosed operating income    1,892  
Operating income (loss):13,677(3,647)(1,450)1,221(773)(567)59
Nonoperating income (expense)1112302148750(2)11
Investment income, nonoperating11123021487 3911
Other nonoperating expense     (41) 
Interest and debt expense(278)(296)(323)(251)   
Other undisclosed loss from continuing operations before equity method investments, income taxes    (295)  
Income (loss) from continuing operations before equity method investments, income taxes:13,510(3,713)(1,559)1,057(1,018)(569)70
Other undisclosed loss from continuing operations before income taxes(3,990)      
Income (loss) from continuing operations before income taxes:9,520(3,713)(1,559)1,057(1,018)(569)70
Other undisclosed income (loss) from continuing operations1,069(265)164    
Income (loss) from continuing operations:10,589(3,978)(1,395)1,057(1,018)(569)70
Income from discontinued operations    40161 
Net income (loss) available to common stockholders, basic:10,589(3,978)(1,395)1,057(978)(408)70
Other undisclosed net income available to common stockholders, diluted1,000      
Net income (loss) available to common stockholders, diluted:11,589(3,978)(1,395)1,057(978)(408)70

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net income (loss):10,589(3,978)(1,395)1,057(978)(408)70
Comprehensive income (loss):10,589(3,978)(1,395)1,057(978)(408)70
Other undisclosed comprehensive loss, net of tax, attributable to parent(53)(33)(67)(11)(7)(8)(5)
Comprehensive income (loss), net of tax, attributable to parent:10,536(4,011)(1,462)1,046(985)(416)65

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: